1
|
Woodard G, Tanoue L, Detterbeck F, Boffa D, Mase V, Blasberg J, Dhanasopon A, Gosangi B, Traube L, Bader A. PP01.12 Increasing Diagnosis of Ground Glass Nodules and Semi-Solid Lung Lesions on Chest CT Scans over the Past Decade. J Thorac Oncol 2023. [DOI: 10.1016/j.jtho.2022.09.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
|
2
|
Osarogiagbon R, Nishimura K, Porta RR, Montuenga L, Giroux D, Suda K, Araujo L, Detterbeck F, Gautschi O, Kerr K, Kneuertz P, Mack P, Matilla J, Nicholson A, Pass H, Presley C, Terra R, Wistuba I, Yang D, Yatabe Y, Travis W, Tsao M, Asamura H, Rusch V, Hirsch F, Carbone D. OA06.04 Constructing a Global Molecular Database for Thoracic Malignancies: The IASLC Molecular Subcommittee Lung Cancer Dataset. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
3
|
Tsukazan MR, Terra R, Santoro I, Fortunato G, Meirelles G, Detterbeck F. P2.13-022 Lung Nodule Survey: One Pathology, Perspectives from Thoracic Surgeon, Pulmonologist and Radiology Point of View. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
4
|
Fang W, Yao X, Antonicelli A, Louie B, Gu Z, Vallieres E, Huang J, Korst R, Detterbeck F. B-002COMPARISON OF SURGICAL APPROACH AND EXTENT OF RESECTION FOR STAGE I AND II THYMIC TUMOURS IN EUROPE, NORTH AMERICA AND ASIA: AN ITMIG RETROSPECTIVE DATABASE GEOGRAPHIC ANALYSIS. Interact Cardiovasc Thorac Surg 2016. [DOI: 10.1093/icvts/ivw260.02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
5
|
Filosso PL, Yao X, Ahmad U, Ruffini E, Antonicelli A, Huang J, Guerrera F, Venuta F, Van Raemdonck D, Travis W, Rimner A, Thomas P, Lucchi M, Rocco G, Weder W, Detterbeck F, Korst R. F-118COMPARISON OF OUTCOMES BETWEEN NEUROENDOCRINE THYMIC TUMOURS AND OTHER SUBTYPES OF THYMIC CARCINOMAS: A JOINT ANALYSIS OF THE EUROPEAN SOCIETY OF THORACIC SURGEONS (ESTS) AND THE INTERNATIONAL THYMIC MALIGNANCY INTEREST GROUP (ITMIG). Interact Cardiovasc Thorac Surg 2015. [DOI: 10.1093/icvts/ivv204.118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
6
|
Antonicelli A, Nosotti M, Guadagnini A, Riva M, Inzoli F, Detterbeck F. F-037 * WATER SEAL'S ONE-WAY ACTION IN CHEST DRAINAGE SYSTEMS: WHEN THE PARADIGM FAILS. Interact Cardiovasc Thorac Surg 2014. [DOI: 10.1093/icvts/ivu167.37] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
Dhamija A, Dhamija A, Kim A, Detterbeck F, Boffa D. F-089MINIMALLY INVASIVE OESOPHAGECTOMY MORE EXPENSIVE THAN OPEN AT NORTH AMERICAN HOSPITAL DESPITE SHORTER LENGTH OF STAY. Interact Cardiovasc Thorac Surg 2013. [DOI: 10.1093/icvts/ivt288.89] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
8
|
Ruffini E, Van Raemdonck D, Detterbeck F, Rocco G, Thomas P, Weder W, Venuta F. 31IN THE ROLE OF SURGERY IN THE MANAGEMENT OF THYMOMAS: STATE OF THE ART. Lung Cancer 2011. [DOI: 10.1016/s0169-5002(11)70168-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
9
|
Detterbeck F, Toker A. Conference discussion: Does a relationship exist between the number of thoracoscopic thymectomies performed and the learning curve for thoracoscopic resection of thymoma in patients with myasthenia gravis? Interact Cardiovasc Thorac Surg 2011; 12:155. [PMID: 21322162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023] Open
|
10
|
|
11
|
Anagnostou V, Lowery F, Syrigos K, Frangia K, Zolota V, Panagopoulos N, Dougenis D, Tanoue L, Detterbeck F, Homer R, Rimm D. Association of expression of bcl-2 with outcome in non-small cell lung cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e22039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e22039 Background: BCL-2 promotes cell survival by inhibiting adapters needed for the activation and cleavage of caspases thus blocking the proteolytic cascade that ultimately dismantles the cell. It is preferentially expressed in squamous cell carcinomas of the lung and has been investigated as a potential prognostic parameter in lung cancer patients with conflicting results. Here, we quantitatively assessed BCL-2 protein expression in two large and independent data sets to investigate the impact of BCL-2 on patient survival. Methods: AQUA, a fluorescent-based method for analysis of in situ protein expression, was used to measure BCL-2 protein levels and classify tumor by BCL-2 expression in a cohort of 180 lung cancer patients from Yale New Haven Hospital (training set). An independent cohort of 360 lung cancer patients from Sotiria General Hospital and Patras University Hospital in Greece was used to validate BCL-2 classification and evaluate outcome (validation set). Results: Tumors expressed BCL-2 in 57% and 53% of the cases in training and validation cohorts respectively and squamous cell carcinomas expressed higher levels of BCL-2 expression compared to adenocarcinomas (mean AQUA score 42 and 26 respectively, p=0.007); BCL-2 was not associated with other standard clinical or pathological characteristics. Survival analysis showed that patients with high BCL-2 expression had a longer median overall survival compared to the low expressers (20 vs 15 months, log rank p=0.016). Multivariate analysis revealed an independent lower risk of death for lung cancer patients with BCL-2 expressing tumors (HR=0.58, 95% CI 0.39–0.86, p=0.006). Conclusions: BCL-2 expression defines a subgroup of patients with a favorable outcome and may be useful for prognostic stratification of lung cancer patients as well as incorporation of BCL-2 into clinical decisions. [Table: see text]
Collapse
Affiliation(s)
- V. Anagnostou
- Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, New Haven, CT; Yale Cancer Center, Yale University School of Medicine, New Haven, CT; Sotiria General Hospital, Athens, Greece; University of Patras, Patras, Greece
| | - F. Lowery
- Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, New Haven, CT; Yale Cancer Center, Yale University School of Medicine, New Haven, CT; Sotiria General Hospital, Athens, Greece; University of Patras, Patras, Greece
| | - K. Syrigos
- Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, New Haven, CT; Yale Cancer Center, Yale University School of Medicine, New Haven, CT; Sotiria General Hospital, Athens, Greece; University of Patras, Patras, Greece
| | - K. Frangia
- Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, New Haven, CT; Yale Cancer Center, Yale University School of Medicine, New Haven, CT; Sotiria General Hospital, Athens, Greece; University of Patras, Patras, Greece
| | - V. Zolota
- Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, New Haven, CT; Yale Cancer Center, Yale University School of Medicine, New Haven, CT; Sotiria General Hospital, Athens, Greece; University of Patras, Patras, Greece
| | - N. Panagopoulos
- Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, New Haven, CT; Yale Cancer Center, Yale University School of Medicine, New Haven, CT; Sotiria General Hospital, Athens, Greece; University of Patras, Patras, Greece
| | - D. Dougenis
- Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, New Haven, CT; Yale Cancer Center, Yale University School of Medicine, New Haven, CT; Sotiria General Hospital, Athens, Greece; University of Patras, Patras, Greece
| | - L. Tanoue
- Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, New Haven, CT; Yale Cancer Center, Yale University School of Medicine, New Haven, CT; Sotiria General Hospital, Athens, Greece; University of Patras, Patras, Greece
| | - F. Detterbeck
- Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, New Haven, CT; Yale Cancer Center, Yale University School of Medicine, New Haven, CT; Sotiria General Hospital, Athens, Greece; University of Patras, Patras, Greece
| | - R. Homer
- Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, New Haven, CT; Yale Cancer Center, Yale University School of Medicine, New Haven, CT; Sotiria General Hospital, Athens, Greece; University of Patras, Patras, Greece
| | - D. Rimm
- Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, New Haven, CT; Yale Cancer Center, Yale University School of Medicine, New Haven, CT; Sotiria General Hospital, Athens, Greece; University of Patras, Patras, Greece
| |
Collapse
|
12
|
Parsons A, Ennis E, Yankaskas B, Parker L, Hyslop W, Detterbeck F. O-071 Helical CT accuracy in the detection of pulmonary metastases. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80204-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
13
|
Rivera M, Detterbeck F, Socinski M, Moore D, Edelman M, Jahan T, Ansari R, Luketich J, Obasaju C, Gralla R. PD-098 Initial results of pre-operative pulmonary function testing in patients with stage I–II Non-Small Cell Lung Cancer (NSCLC) treated with neoadjuvant chemotherapy with gem citabine-containing regimens. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80431-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
14
|
Gralla R, Edelman M, Detterbeck F, Jahan T, Loesch D, Limentani S, Govindan R, Obasaju C, Bloss L, Socinski M. P-617 Evaluating the impact of neoadjuvant chemotherapy and surgeryon quality of life (QL) in patients with early stage NSCLC: A prospective analysis of the GINEST project. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)81110-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
15
|
Socinski M, Detterbeck F, Gralla R, Edelman M, Jahan T, Loesch D, Limentani S, Govindan R, Bloss L, Obasaju C. O-115 Induction chemotherapy with gemcitabine-containing regimensin stage I–II non-small cell lung cancer (NSCLC): Initial results of the GINEST* Project. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80249-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
16
|
Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Johnson D, Goldberg M, Detterbeck F, Shepherd F, Burkes R, Winton T, Deschamps C, Livingston R, Gandara D. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Thorac Cardiovasc Surg 2001; 121:472-83. [PMID: 11241082 DOI: 10.1067/mtc.2001.112465] [Citation(s) in RCA: 226] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
OBJECTIVE The rate of complete resection (50%) and the 5-year survival (30%) for non-small cell lung carcinomas of the superior sulcus have not changed for 40 years. Recently, combined modality therapy has improved outcome in other subsets of locally advanced non-small cell lung carcinoma. This trial tested the feasibility of induction chemoradiation and surgical resection in non-small cell lung carcinoma of the superior sulcus with the ultimate aim of improving resectability and survival. METHODS Patients with mediastinoscopy-negative T3-4 N0-1 superior sulcus non-small cell lung carcinoma received 2 cycles of cisplatin and etoposide chemotherapy concurrent with 45 Gy of radiation. Patients with stable or responding disease underwent thoracotomy 3 to 5 weeks later. All patients received 2 more cycles of chemotherapy and were followed up by serial radiographs and scans. Survival was calculated by the Kaplan-Meier method and prognostic factors were assessed for significance by Cox regression analysis. RESULTS From April 1995 to September 1999, 111 eligible patients (77 men, 34 women) were entered in the study, including 80 (72.1%) with T3 and 31 with T4 tumors. Induction therapy was completed as planned in 102 (92%) patients. There were 3 treatment-related deaths (2.7%). Cytopenia was the main grade 3 to 4 toxicity. Of 95 patients eligible for surgery, 83 underwent thoracotomy, 2 (2.4%) died postoperatively, and 76 (92%) had a complete resection. Fifty-four (65%) thoracotomy specimens showed either a pathologic complete response or minimal microscopic disease. The 2-year survival was 55% for all eligible patients and 70% for patients who had a complete resection. To date, survival is not significantly influenced by patient sex, T status, or pathologic response. CONCLUSIONS (1) This combined modality treatment is feasible in a multi-institutional setting; (2) the pathologic complete response rates were high; and (3) resectability and overall survival were improved compared with historical experience, especially for T4 tumors, which usually have a grim prognosis.
Collapse
Affiliation(s)
- V W Rusch
- Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Abstract
BACKGROUND Combined-modality therapy has become standard for many patients with non-small cell lung cancer. Although surgical resection offers the best chance for long-term survival, the limited number of resectable patients and the presence of occult micrometastatic disease has limited the effectiveness of this modality alone. METHODS The authors reviewed several trials involving the use of induction chemotherapy in managing resectable non-small cell lung cancer. RESULTS Extensive phase II experience in patients with stage III disease has confirmed the feasibility of this approach. Unfortunately, heterogeneous patient populations and treatment regimens limit the ability to draw firm conclusions from these trials alone. While the phase III experience has been limited, long-term follow-up is now available suggesting that induction therapy may have a beneficial impact on survival, especially for those patients who can be sufficiently downstaged. Recent phase II trials have included stage III patients who have traditionally been considered inoperable. Although encouraging, the role of surgery after chemoradiotherapy for this population of patients remains undefined. CONCLUSIONS Results from ongoing randomized trials studying the impact of induction therapy on well-defined patient populations will be necessary before the optimal regimen and patient population can be identified.
Collapse
Affiliation(s)
- T A Hensing
- Multidisciplinary Thoracic Oncology Program, University of North Carolina, Chapel Hill 27519, USA
| | | | | |
Collapse
|
18
|
Abstract
A consistent, planned approach to thymectomy for patients with myasthenia gravis has been used at the University of North Carolina since 1977. This involves a sternotomy, with excision of the entire thymus and adjacent fatty tissues from the thyroid to the diaphragm and laterally to 1 cm from each phrenic nerve. Between 1977 and 1993, 100 consecutive patients were treated in this manner with no mortality. Eight-four percent of patients were extubated in the operating room or within 1 hour of surgery, and no patients experienced postoperative respiratory difficulty. After a mean follow-up of 65 months, 78% of all patients improved by at least one modified Osserman classification, and 69% of patients with preoperative class I, II, or III disease (maximal preoperative severity) are in pharmacological remission. We conclude that transsternal thymectomy is associated with minimal morbidity and no mortality, and results in long-term improvement in symptoms for patients with myasthenia gravis.
Collapse
Affiliation(s)
- W Scott
- Division of Cardiothoracic Surgery, University of North Carolina School of Medicine, Chapel Hill, USA
| | | |
Collapse
|
19
|
Affiliation(s)
- E Ransom
- University of North Carolina at Chapel Hill, 27599-7010, USA
| | | | | | | |
Collapse
|
20
|
Jolly PC, Hutchinson CH, Detterbeck F, Guyton SW, Hofer B, Anderson RP. Routine computed tomographic scans, selective mediastinoscopy, and other factors in evaluation of lung cancer. J Thorac Cardiovasc Surg 1991; 102:266-70; discussion 270-1. [PMID: 1865700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Routine computed tomographic scan is advocated as the best noninvasive method of evaluating mediastinal nodes for cancer spread. Positive studies should be confirmed histologically. Large size, central location, unfavorable cell type, poor cellular differentiation of the primary cancer, and weight loss also correlate with increased likelihood of mediastinal involvement.
Collapse
Affiliation(s)
- P C Jolly
- Virginia Mason Medical Center, Seattle, Wash
| | | | | | | | | | | |
Collapse
|
21
|
Detterbeck F, Langenbach R, Smith J, Roxe DM. Recurrent fever of unknown origin with cimetidine-induced interstitial nephritis. J Infect Dis 1983; 148:1132. [PMID: 6655294 DOI: 10.1093/infdis/148.6.1132] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
|